scholarly journals Study on Histopathological Correlation with ER, PR, and HER 2 Neu Receptor Status in Breast Carcinoma and its Prognostic Importance

2019 ◽  
Vol 5 (1) ◽  
pp. 2130-2136 ◽  
Author(s):  
Mahendra Singh ◽  
Jagdish Kumar ◽  
Anita Omhare ◽  
Vandana Mishra ◽  
Chayanika Kala
Keyword(s):  
Breast Carcinoma ◽  
Receptor Status ◽  
Histopathological Correlation ◽  
Her 2 ◽  
Prognostic Importance

Identification of risk factors in mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging (MRI)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 614-614
Author(s):  
J. R. Bernard ◽  
L. A. Vallow ◽  
S. Packianathan ◽  
D. G. Feigel ◽  
E. R. DePeri ◽  
...  
Keyword(s):  
Risk Factors ◽  
Breast Carcinoma ◽  
Tumor Size ◽  
Menopausal Status ◽  
Contralateral Breast ◽  
Nodal Status ◽  
Newly Diagnosed ◽  
Receptor Status ◽  
Her 2 ◽  
Contralateral Carcinoma

614 Background: An analysis of preoperative bilateral breast MRI at our institution suggests that approximately 1/3 of patients with newly diagnosed breast cancer may have a mammographically occult, but MRI-evident, contralateral breast abnormality. A number of these patients will have pathologic confirmation of carcinoma in the contralateral breast. Identification of risk factors to predict which patients are at high risk for having a mammographically occult contralateral carcinoma was performed. Methods: MRI results of 401 women with newly diagnosed breast carcinoma who underwent MRI were reviewed (overall group; OG). Patients with a contralateral abnormality identified only by MRI were analyzed to determine the incidence of contralateral carcinoma. In addition, the following risk factors were evaluated: Age at diagnosis, menopausal status, tumor size, nodal status, ipsilateral tumor histology, tumor grade, hormone receptor status, Her-2/neu receptor status, and whether the patient had a palpable vs. mammographically detected abnormality. Results: Pathologically confirmed contralateral carcinoma (CC) was found in 13 patients (3.2%). Similar percentages of patients in both groups (OG and CC) were noted in regard to tumor size, histology, grade, nodal status, Her-2/neu receptor status, and method of detection (palpable vs. mammographic). However, median patient age was 71 (CC) vs. 62(OG); 92% (12/13) were postmenopausal (CC) compared to 75% (OG); and 100% were ER positive (CC) vs. 81% percent (OG). Conclusions: Older, postmenopausal women who have ER + tumors may have a higher likelihood of having synchronous, contralateral, mammographically occult, MRI-detected breast carcinoma. Preoperative MRI may be beneficial in patients with similar risk factors; however, further follow up and additional experience is needed for confirmation of these findings. No significant financial relationships to disclose.

scholarly journals Influence of Age, Estrogen receptor (ER),Progesterone receptor (PR) and Epidermal growth factor -2 (HER-2) in Breast Carcinoma Patient in correlation with Radionuclide Bone Scan – Single Institute Based Experience

2021 ◽  
Vol 22 (2) ◽  
pp. 114-118
Author(s):  
Samira Sharmin ◽  
Farida Yasmin ◽  
Debabrata Ghosh ◽  
Afroza Naznin ◽  
Azmal Kabir Sarker ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Bone Metastases ◽  
Bone Scan ◽  
Triple Negative ◽  
Receptor Status ◽  
Visceral Involvement ◽  
Multiple Metastases ◽  
Visceral Metastases ◽  
Her 2 ◽  
Solitary Metastases

Background: Breast carcinoma is a common type of malignancy in women worldwide. Radionuclide bone scintigraphy is recognized choice of investigation for the detection of bone metastases both in asymptomatic and symptomatic patients. Biomarkers like Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal growth factor -2 (HER-2) also play important role in the management and prognosis of breast cancer. The study was aimed to find out the relationship between the MDP bone scan findingsand hormone receptor and HER-2 status of breast carcinoma patients referred to the Institute of Nuclear Medicine and Allied Sciences (INMAS), Mitford, Dhaka. Patients and Methods: This cross sectional study was conducted among 301 breast carcinoma patients between January 2018 and December 2019. Planar bone scan and SPECT (if needed) was done to all the patients after intravenous injection of 99mTc-MDP. Receptor status (ER, PR and HER-2) were documented from the patient’s medical records. Breast tumors were classified as (a) Triple positive- HER2-, ER-, and PR-positive) (b) Triple negative- HER2-, ER-, and PR-negative (c) Hormonereceptor (HR) positive (ER+/PR+) with HER-2 negative and d) HR negative (ER-/PR-) with HER-2 positive.Patients were broadly grouped according to age as A. less than 50 years (n = 59) and B. more than 50 (n = 260 ) years. Results: The mean age of the patients enrolled for this study was 59.02±9.3 with range of 32 to 81 years. Out of the 301 patients, positive bone scans were found in 105 (34.8%) and negative bone scan were found 196 (66.2%). Patients of group A (<50years) with triple negative and HR+/HER-status had no bone or bone with visceral metastases. Triple positive subtype had 2 bone metastases, and HR-/HER-2+ subtype had 2 bone metastases and 1 had bone with visceral metastases. Group B (> 50years) patients having HR+/HER2- receptor status showed 16% solitary metastases, 53.2% multiple metastases, 33.3% extensive bony metastases, 13.6% bone with visceral metastases. Triple negative subtype showed 36.0 % solitary metastases, 19.1% bone with visceral metastases. Triple positive subtype group had 40.0% solitary metastases, 34.0 % multiple metastases, 66.7% extensive bony metastases, and 13.6% bone with visceral metastases. HR-/HER-2+ subtype group had 8% solitary metastases, 12.8% multiple metastases, and 18.2 % bone metastases with visceral involvement Overall relationship between bone scan and hormone receptor subtype, showed that most of the patients had HR+/ HER-2-(35.2%) subtype and 25.6% patient had triple positive, 23.3% patient had triple negative and 15.9% patient had HR-/HER-2 – receptor subtype. This study showed the visceral involvement with bone metastases (13 % in HR+/HER-2- 52.2 % in triple negative, 13 % in triple positive, 21.7 % in HR-/HER-2+subtype). Highest bone only metastases (35) in triple positive and HR+/HER-2-(31) subtype. Most of the patiens who had bone metastases with visceral involvement belong to triple negative (52.2%) and HER-2 subtypes -HR-/HER-2+ (21.7%). The result was significant (P<0.001). Conclusion: It is observed from this study that triple positive and HR+/HER-2- were more likely to develop bone metastases than triple negative and HR-/HER-2-. Patients with bone scan negative and HR-/HER-2- or triple negative receptor status most likely develop visceral metastases Bangladesh J. Nuclear Med. 22(2): 114-118, Jul 2019

A PROSPECTIVE STUDY ON RELATION OF HISTOLOGICAL GRADE AS WELLAS HORMONE RECEPTOR PROFILE IN LOCALLY ADVANCED BREAST CARCINOMA PATIENTS IN RESPONSE TO NEOADJUVANT CHEMOTHERAPY

2021 ◽  
pp. 59-61
Author(s):  
Samir Ranjan ◽  
Arun Gupta
Keyword(s):  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Prospective Study ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Lobular Carcinoma ◽  
Locally Advanced ◽  
Receptor Status ◽  
Her 2 ◽  
A Prospective Study

Introduction: Inltrating ductal carcinoma being the most common type of carcinoma (70%), lobular carcinoma is the 2nd most common followed by smaller groups such as medullary, mucinous,comedo, paget's disease, papillary, tubular and inammatory carcinoma. Aims and objectives:To establish incidence and correlation between ER, PR, HER 2 neu receptor status, histology with different patient proles. Assessment of therapeutic effectivity and its relation with receptor status and histology after neoadjuvant chemotherapy. Material and methods: This will be an institution-based observational and prospective study. Lab studies- hemoglobin, total count, fasting and postprandial blood sugar, urea, creatinine, albumin and total protein Pretested and predesigned perform Conclusion: This study shows that age group is an important factor for developing breast carcinoma, which was more prevalent in premenstrual population.

scholarly journals The Association of HER-2 Over-expression in Relation to Hormonal Receptor Status and Common Clinico-pathological Parameters in Breast Carcinoma

2019 ◽  
Vol 16 (2) ◽  
pp. 59-67
Author(s):  
Md Jahidul Islam ◽  
ABM Bayezid Hossain ◽  
Shaheen Akter ◽  
Sadia Afroz
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Tumour Size ◽  
Menopausal Status ◽  
Receptor Status ◽  
Over Expression ◽  
Hormonal Receptor ◽  
Er Positive ◽  
Her 2 ◽  
Hormonal Receptor Status

Objective: To determine the association of Human Epidermal growth factor Receptor2 (HER-2) with hormonal receptor status and common clinico-pathological parameters of breast carcinoma. Study Design: Cross-sectional, observational study. Place and Duration of Study: Department of Surgery, Sir Salimullah Medical College Mitford Hospital, Dhaka, Bangladesh during the period from January 2009 to December 2009. Methodology: A total of 100 patients of female breast carcinoma with HER-2 status, hormonal receptor profile and clinico-pathological parameters were included in this study. Patient's age, menopausal status, tumour size, lymph node status, Estrogen Receptor (ER) and Progesterone Receptor (PR) status were evaluated and their association was determined with H.ER-2 over expression using the chi-square test for analysis. Results: Of these 100 cases, mean age of diagnosis was 48 years and mean tumour size 4.4 cm. Lymph node metastases were present in 50% cases. HER-2 over-expression was seen in 29% cases, while ER and PR expression was seen in 61 % and 43% respectively. ER and PR showed inverse association (p <0.05) with HER-2 while positive association was seen with tumour size and lymph node metastases (p <0.05). No association was seen with menopausal status. Further, among 61 ER positive cases, 4 cases also HER-2 over expressed. Conclusion: The study had indicated that Her-2 may be a powerful predictor of poor prognosis as its over-expression was strongly directly associated with tumor size and lymph node involvement and inversely associated with hormonal receptor status of breast carcinoma. ER positive cases can also be HER-2 over expressed (4%), so ER status cannot be used to select tumours for evaluation of HER-2 status. As treatment modalities of ER positive and HER-2 over expressed is different, so all the patients should be studied with both receptor and treat accordingly. Journal of Surgical Sciences (2012) Vol. 16 (2) : 59-67

scholarly journals Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma

BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Fabíola E Rosa ◽  
Sara M Silveira ◽  
Cássia GT Silveira ◽  
Nádia A Bérgamo ◽  
Francisco A Moraes Neto ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Real Time ◽  
Rt Pcr ◽  
Her 2 ◽  
Chromogenic In Situ Hybridization

scholarly journals Clinical Profile of Patients Presenting with Breast Cancer in Nepal

2013 ◽  
Vol 10 (3) ◽  
pp. 3-7 ◽  
Author(s):  
Sandhya Chapagain Acharya ◽  
AK Jha ◽  
T Manandhar
Keyword(s):  
Breast Cancer ◽  
Locally Advanced ◽  
Tnm Staging ◽  
Clinical Profile ◽  
Stage Iii ◽  
Disease Stage ◽  
Case Report Form ◽  
South Asian Population ◽  
Receptor Status ◽  
Her 2

Background Breast cancer is the second most common cancer in women in Nepal. Even though the evaluation and treatment of patients is done as per western guidelines, there are considerable variations in risk factors, presenting stage and prognostic factors such as receptor status. Objective To evaluate the clinical profile of patients presenting with breast cancer in Nepal. Method The study was conducted at Department of Radiotherapy and Oncology, Bir Hospital and Department of Radiation Oncology, BP Koirala Memorial Cancer Hospital, Bharatpur from 16th July 2007 to 15th June 2008 for a period of one year and 114 patients were enrolled. Detailed history, clinical examination and necessary investigations performed. Histological features including receptor status were recorded. Tumor Node Metastasis (TNM) staging system was as per American Joint Committee on Cancer (AJCC), fifth edition. Data was collected in preformed case report form and was managed using SPSS version 13. Results The incidence was high (34.2%) among perimenopausal women age ranging from 41 to 50. The majority of women presented with lump (98.2%) and others with pain (21.9%), nipple retraction (16.7%), ulceration (7.9%), discharge (7%), or symptoms of metastasis (6.1%). Regarding receptor status, the majority (64.0%) were Estrogen receptor (ER) and Progesterone receptor (PR) negative with 21.9 percent. ER+PR+, Younger women were more likely to be both ER and PR negative. Where available, Her-2 immunohistochemistry showed that 45.0 % of post menopausal women were Her-2 neative, compared to 64.0 % of premenopausal women. Incidence of Triple negative disease was 41.3 %. The most common stage at presentation was stage III (26.3%). Conclusion Majority of patients were perimenopausal, presenting with locally advanced disease (Stage III and Stage II) and with average tumor size two to five cm and were hormonal receptor negative. These findings are similar to other South Asian population but is inverse than profile reported in Western populations.Kathmandu University Medical Journal | VOL.10 | NO. 3 | ISSUE 39 | JUL- SEP 2012  | Page 3-7 DOI: http://dx.doi.org/10.3126/kumj.v10i3.8009

Sign in / Sign up

Export Citation Format

Share Document